RO 7515629
Alternative Names: RG-6353 Roche; RO-7515629Latest Information Update: 02 May 2024
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Apr 2024 Hoffmann-La Roche terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV), due to sponsor decision (not related to safety, efficacy or quality) (NCT05769959)
- 15 Feb 2024 Discontinued - Phase-I/II for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV) (Roche pipeline, February 2024)
- 06 May 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT05769959)